AUTLAutolus Therapeutics plc
Price
+18%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growing in the filings, the market undecided.
Charts
As reported to the SEC, without any scoring.
Autolus Therapeutics plc (AUTL) reported revenue of $46M in Q2 2026 (quarter ended Jun 30, 2026), up 118% from the same quarter a year earlier. That came with a gross margin of 55% and net loss of $39M. For the full year FY2025, revenue was $75M (+645% year on year) and net income −$288M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 20261 Gross margin percentage represents gross margin (net product revenue less cost of sales) divided by net product revenue.Earnings release · press release
- Aug 3, 2026On August 3, 2026, the Company announced an increase in full year 2026 guidance for AUCATZYL® net product revenue to $140 million to $150 million, from between $120 million to $135 million.Regulation FD disclosure · Form 8-K
- Aug 3, 2026Perceptive Senior Secured Notes Facility On July 30, 2026 (the “Closing Date”), Autolus Therapeutics plc (the “Company”) entered into a Note Purchase Agreement and Guaranty (the “Note Purchase Agreement”) with certain subsidiaries of the Company, as guarantors, the noteholders party thereto and Perceptive Credit …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.